“Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria”, J of Skin, vol. 7, no. 6, p. s299, Nov. 2023, doi: 10.25251/skin.7.supp.299.